Wednesday, December 09, 2015 5:04:37 PM
Jack, you are right, I certainly do want NWBO to succeed, not only for my own benefit, but even more so for those suffering from cancer. Hell, one day it could be someone I love, or even me.
I agree, I don't give an anonymous report much credibility, but like our friend Adam, they did a good job taking selective information and painting a picture that is none the flattering to NWBO. It is serious enough that Woodford called for an investigation to clear the air of this misinformation.
I have taken one example from the report and found issues with it myself. That had to do with them claiming the patents were sold, when in reality they appear to have been assigned as security collateral for a loans from Toucan, and later Four M. However, there is still a question in my mind as to why several years later they appear to still be assigned to Four M. I'm sure someone could clear that one up pretty quickly.
Then there is the Malik suspension/investigation, which is underway. Again, there should be a clear explanation that shouldn't require a lot of work to investigate and explain. It just needs to happen. Otherwise, one our independent directors is in a bad light and people will accuse the board of being self-serving or rubber-stamping Linda's decisions.
Finally, there is the issue over the Israel treatments and what is going on there; and where those revenues and costs are accounted for (assuming people really are being treated with L). The company doesn't need to be accused of revenue recognition issues at this stage of its development. I'm sure there is an explanation.
In my mind, everything else in the report is pure rubbish. I know their intent and purpose, and many of these other things have been bantered about forever on these boards.
I don't think clearing these things up lends credibility to the report, as much as it will lend credibility to the management of the company. I wish Linda could be more open on some of the other things around where the money is being spent, but I trust that it is being spent in areas to advance the product through the trials and commercialization. I believe she is keeping those things close to the vest for good reason.
As you said, ultimately it comes down to approval, because everything else won't matter if that doesn't happen. On that front, I am pretty optimistic. Screw the Shorts!!!!
Long and strong with many, many shares here. Not selling any until the game is over.
I agree, I don't give an anonymous report much credibility, but like our friend Adam, they did a good job taking selective information and painting a picture that is none the flattering to NWBO. It is serious enough that Woodford called for an investigation to clear the air of this misinformation.
I have taken one example from the report and found issues with it myself. That had to do with them claiming the patents were sold, when in reality they appear to have been assigned as security collateral for a loans from Toucan, and later Four M. However, there is still a question in my mind as to why several years later they appear to still be assigned to Four M. I'm sure someone could clear that one up pretty quickly.
Then there is the Malik suspension/investigation, which is underway. Again, there should be a clear explanation that shouldn't require a lot of work to investigate and explain. It just needs to happen. Otherwise, one our independent directors is in a bad light and people will accuse the board of being self-serving or rubber-stamping Linda's decisions.
Finally, there is the issue over the Israel treatments and what is going on there; and where those revenues and costs are accounted for (assuming people really are being treated with L). The company doesn't need to be accused of revenue recognition issues at this stage of its development. I'm sure there is an explanation.
In my mind, everything else in the report is pure rubbish. I know their intent and purpose, and many of these other things have been bantered about forever on these boards.
I don't think clearing these things up lends credibility to the report, as much as it will lend credibility to the management of the company. I wish Linda could be more open on some of the other things around where the money is being spent, but I trust that it is being spent in areas to advance the product through the trials and commercialization. I believe she is keeping those things close to the vest for good reason.
As you said, ultimately it comes down to approval, because everything else won't matter if that doesn't happen. On that front, I am pretty optimistic. Screw the Shorts!!!!
Long and strong with many, many shares here. Not selling any until the game is over.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
